DB:0OG

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

OrganiGram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada.


Snowflake Analysis

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has OrganiGram Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0OG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-4.5%

0OG

-2.4%

DE Pharmaceuticals

-1.4%

DE Market


1 Year Return

-79.0%

0OG

11.1%

DE Pharmaceuticals

8.0%

DE Market

Return vs Industry: 0OG underperformed the German Pharmaceuticals industry which returned 11.7% over the past year.

Return vs Market: 0OG underperformed the German Market which returned 8.1% over the past year.


Shareholder returns

0OGIndustryMarket
7 Day-4.5%-2.4%-1.4%
30 Day-21.9%-8.6%-1.2%
90 Day-20.2%0.6%12.6%
1 Year-79.0%-79.0%14.7%11.1%10.4%8.0%
3 Year-28.2%-28.2%30.3%15.1%4.7%-3.7%
5 Year373.7%373.7%23.5%2.2%15.9%0.3%

Price Volatility Vs. Market

How volatile is OrganiGram Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is OrganiGram Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 0OG (€1.07) is trading below our estimate of fair value (€9.95)

Significantly Below Fair Value: 0OG is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 0OG is unprofitable, so we can't compare its PE Ratio to the DE Pharmaceuticals industry average.

PE vs Market: 0OG is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0OG's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0OG is good value based on its PB Ratio (1x) compared to the DE Pharmaceuticals industry average (3.1x).


Next Steps

Future Growth

How is OrganiGram Holdings forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?

76.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0OG is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.2%).

Earnings vs Market: 0OG is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 0OG's is expected to become profitable in the next 3 years.

Revenue vs Market: 0OG's revenue (25.9% per year) is forecast to grow faster than the German market (5.8% per year).

High Growth Revenue: 0OG's revenue (25.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0OG's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has OrganiGram Holdings performed over the past 5 years?

-29.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0OG is currently unprofitable.

Growing Profit Margin: 0OG is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0OG is unprofitable, and losses have increased over the past 5 years at a rate of 29.2% per year.

Accelerating Growth: Unable to compare 0OG's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0OG is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.8%).


Return on Equity

High ROE: 0OG has a negative Return on Equity (-37.49%), as it is currently unprofitable.


Next Steps

Financial Health

How is OrganiGram Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 0OG's short term assets (CA$162.6M) exceed its short term liabilities (CA$31.6M).

Long Term Liabilities: 0OG's short term assets (CA$162.6M) exceed its long term liabilities (CA$82.0M).


Debt to Equity History and Analysis

Debt Level: 0OG's debt to equity ratio (26.7%) is considered satisfactory.

Reducing Debt: 0OG's debt to equity ratio has reduced from 31.6% to 26.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if 0OG has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 0OG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is OrganiGram Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 0OG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 0OG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0OG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0OG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0OG's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Greg Engel (55 yo)

3.42yrs

Tenure

CA$1,074,643

Compensation

Mr. Gregory Engel, also known as Greg, has been Chief Executive Officer of OrganiGram Holdings Inc. since March 13, 2017. Mr. Engel has served in a number of senior-level and executive positions in related ...


CEO Compensation Analysis

Compensation vs Market: Greg's total compensation ($USD804.53K) is about average for companies of similar size in the German market ($USD787.28K).

Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Gregory Engel
CEO & Director3.42yrsCA$1.07m0.039%
CA$ 77.3k
Derrick West
Chief Financial Officerno dataCA$469.00k0.0049%
CA$ 9.8k
Timothy Emberg
Senior Vice President of Sales & Commercial Operations2.83yrsCA$563.50kno data
Paolo De Luca
Chief Strategy Officer0.42yrCA$852.71k0.024%
CA$ 47.3k
Matt Rogers
Vice President of Operationsno datano data0.011%
CA$ 23.0k
Amy Schwalm
Vice President of Investor Relations1.58yrsno datano data
Helen Martin
Senior VP of Strategic & Legal Affairs and Company Secretary1.33yrsno datano data
Julie Chamberlain
Vice President of Marketing0.083yrno datano data
James Cavanagh
Chief of Staffno datano datano data
Larry Rogers
Vice President of International Business Development2.83yrsCA$222.73kno data
Peter Hanson
Director of Finance2.67yrsCA$143.13kno data

1.6yrs

Average Tenure

50yo

Average Age

Experienced Management: 0OG's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Gregory Engel
CEO & Director3.42yrsCA$1.07m0.039%
CA$ 77.3k
Derrick West
Chief Financial Officerno dataCA$469.00k0.0049%
CA$ 9.8k
Peter Amirault
Independent Chairman & Lead Director2.42yrsCA$502.60k0.082%
CA$ 164.9k
Stephen Smith
Independent Director0.50yrno data0.0053%
CA$ 10.6k
Dexter D. John
Independent Director1.67yrsCA$283.45k0.0030%
CA$ 6.1k
Kenneth James Manget
Independent Director0.50yrno datano data
Geoffrey Machum
Independent Director0.50yrno data0.0023%
CA$ 4.6k
Sherry Porter
Independent Director1.67yrsCA$280.71k0.010%
CA$ 20.1k

1.7yrs

Average Tenure

59yo

Average Age

Experienced Board: 0OG's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 0OG insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.5%.


Top Shareholders

Company Information

OrganiGram Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: OrganiGram Holdings Inc.
  • Ticker: 0OG
  • Exchange: DB
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$315.101m
  • Listing Market Cap: CA$200.421m
  • Shares outstanding: 194.51m
  • Website: https://www.organigram.ca

Number of Employees


Location

  • OrganiGram Holdings Inc.
  • 35 English Drive
  • Moncton
  • New Brunswick
  • E1E 3X3
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OGITSX (The Toronto Stock Exchange)YesCommon SharesCACADAug 2014
OGINasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDAug 2014
0OGDB (Deutsche Boerse AG)YesCommon SharesDEEURAug 2014
0VB6LSE (London Stock Exchange)YesCommon SharesGBCADAug 2014

Biography

OrganiGram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, cannabis oils, and pre-rolls for adult recreational cons ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/05 21:35
End of Day Share Price2020/08/05 00:00
Earnings2020/05/31
Annual Earnings2019/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.